Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation
CureVac N.V. (NASDAQ:CVAC) and GSK plc (NYSE:GSK) have started a Phase 1 trial of the modified COVID-19 mRNA vaccine candidate, administered as a…
China-Based Jemincare Inks Prostate Cancer Drug Pact With Roche’s Genentech
After penning a deal with Orion in May for a non-opioid pain drug, Jemincare is back at the…
Astellas’ Menopause Drug Under FDA Review
The FDA accepted Astellas Pharma Inc’s (OTC:ALPMF) menopause treatment for approval five months after the therapy hit a speed bump in…
Arcturus’ COVID-19 Booster Shows Durability Against Omicron Variants
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) announced updated data from its ongoing ARCT-154 booster clinical trial. The new results demonstrate a broad…
89bio Shares Climb After Concluding Enrolment In Mid-Stage NASH Study
89bio (NASDAQ: ETNB) has completed enrollment in ENLIVEN, the Phase 2b trial of pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH).
BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial
BridgeBio Pharma Inc (NASDAQ:BBIO) has dosed the first patient in its Phase 1 trial of BBP-671, an investigational oral therapy for…
FDA Clears Curis’ Lymphoma Study, Keeping Leukemia Trial Still Stalled
The FDA has lifted the partial clinical hold on Curis Inc’s (NASDAQ:CRIS) TakeAim Lymphoma Phase 1/2 study of emavusertib after reviewing the…
If You Invested $1,000 In Johnson & Johnson Stock At Its COVID-19 Pandemic Low, Here’s How Much You’d Have Now
Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.
Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock
Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile.
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat…